A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology
Phase of Trial: Phase III
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Flortaucipir F 18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- Sponsors Avid Radiopharmaceuticals
- 09 Jun 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2017.
- 09 Jun 2017 Planned primary completion date changed from 1 May 2017 to 1 Dec 2017.
- 16 Sep 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.